Prevalence of human papillomavirus infection in oocyte donors and women treated for infertility: An observational laboratory-based study☆

Hana Jaworek a,1, Blazena Zborilova b,1, Vladimira Koudelakova a, Jana Brezinova c, Jana Vrblkova a, Ivana Oborna b,*, Marian Hajducha d,∗

a Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, 77900, Czech Republic
b Fertimed Ltd., Olomouc, 77900, Czech Republic
c Arleta IVF Ltd., Kostelec nad Orlici, 517 41, Czech Republic
d Cancer Research Czech Republic, Olomouc, 77900, Czech Republic

Keywords:
Human papillomavirus
Infertility
In vitro fertilization
Pregnancy
Oocyte donor

1. Introduction

Infertility remains a highly prevalent global problem, affecting about 10% of reproductive-aged couples worldwide in the twenty-first century [1,2]. Sexually transmitted infections (STIs) like Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum are widely believed to cause fertility alternations [3]. Reproductive alternations may also be associated with viral STIs including human immunodeficiency virus (HIV), human cytomegalo-virus (HCMV), human herpes virus (HSV), adeno-associated viruses, and human papillomavirus (HPV). The impact of viral STIs on human fertility is not well understood [4,5].

STIs could also be a problem in oocyte donors who are routinely screened for the HIV1/2, Hepatitis B/C and Treponema pallidum infections according to the European Commission Directive 2006/17/EC of the Czech Republic. In cases of suspicious infection, additional testing may be required (e.g. HCMV, malaria, Trypanosoma cruzi and human T-lymphotropic virus I). However, testing for HPV infection is not demanded.

HPV infections are prevalent STIs with a global prevalence of about 12%. The highest prevalence is observed in sexually active women under 25 years of age [6]. Low-risk HPV (lrHPV) genotype
infection causes only benign lesions like genital warts. The high-risk HPV (hrHPV) genotypes cause several premalignant and malignant lesions in the anogenital and aero-digestive tracts [7,8]. Moreover, the potential influence of HPV infection to human fertility alterations was suggested by recent studies. Nonetheless, the exact impact of HPV infection on human fertility remains uncertain [9,10].

The aim of this study was to systematically investigate the prevalence of cervical HPV infection in two groups, females treated for infertility (IW) and oocyte donors (OD). The second objective was to clarify the influence of HPV infection on pregnancy and abortion rates in women undergoing in vitro fertilization (IVF) or in recipients of donated oocytes.

2. Material and methods

2.1. Ethical considerations

Study proposals were approved by the Ethics Committee of the Faculty of Medicine and Dentistry of Palacky University and the University Hospital Olomouc in compliance with the Helsinki Declaration. All study participants provided signed informed consent for the use of their collected samples and completed a questionnaire on their health status and sexual behaviour.

2.2. Clinical specimen collection

Samples were collected from women from March 2013 to October 2015 in two Czech fertility centres; Fertimed Ltd. in Olomouc and Arleta IVF Ltd. in Kostelec nad Orlicí which operate in the same geographical region. The inclusion criteria for oocyte donors were according to the European Commission Directive 2004/23/ES and the Czech Directive 296/2008, as amended. Inclusion criteria for women from infertile couples were: duration of infertility longer than one year, infertility due to various causes, and age between 18 and 49 years of age.

Cervical swabs were taken from oocyte donors (n = 207) and from women before planned IVF/IVF + ICSI treatments (n = 945) to test the presence of a spectrum of hrHPV and lHrPV. Oocyte recipients (n = 87) were not tested for HPV DNA presence. Cervical brushes were rinsed in cobas® HDR Cell Collection Media (Roche Diagnostics GMBH, Mannheim, Germany). All samples for molecular testing were stored and transported at room temperature according to the manufacturer’s recommendations.

The analysis included women who underwent IVF/IVF + ICSI (n = 362), or who became pregnant spontaneously (n = 46) within 6 months after sampling without any reproductive treatment. The numbers of pregnancies (documented by vaginal ultrasound) and abortions were evaluated. In the IVF/IVF + ICSI group, only women with a transfer of one or two fresh embryos from own oocytes were included. Only 45 (21.7%) out of 207 oocyte donors were included in the analyses since HPV screening was performed within 6 months after HPV sampling. All study participants tested negative for HIV1/2, Hepatitis B and C, Chlamydia trachomatis, and Treponema pallidum. No clinical symptoms of herpes or HPV infection were detected in these patients.

2.3. HPV DNA detection

All samples were tested for HPV DNA using the cobas® 4800 HPV Test (Roche Diagnostics GMBH, Mannheim, Germany) according to the manufacturer’s recommendations [11]. After analysis, DNA extracted using a cobas x 480 instrument was subjected to HPV DNA detection and genotyping using PapilloCheck®- HPV Screening (Greiner Bio-One, Freckhausen, Germany) [13]. In 40 samples where cobas® 4800 HPV Test and PapilloCheck®- HPV Screening were not concordant, LMNX Genotyping Kit HPV GP (Diasys, Rijswijk, The Netherlands) [14] was used for confirmation as described previously [12].

Concordant HPV result for a given sample was obtained when at least two methods gave consistent results for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Positive detection of HPV53, 70, 73, 82, 6, 11, 40, 42, 43 and 44/55 was based only on PapilloCheck HPV-Screening results. Samples positive for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, or 82 were considered hrHPV positive.

2.4. Statistical analysis

The R statistical software (version 3.5.0; R Core Team, R Foundation for Statistical Computing [http://www.r-project.org]) was used for data evaluation. Any associations between hrHPV positive status and fertility outcomes or social, behavioral and clinical characteristics were assessed using Fisher’s exact test, Pearson’s chi-squared test or Wilcoxon exact test, as appropriate. Data from questionnaires were analysed only if available. Multivariate analysis was performed using multivariate logistic regression model with adjustment to categorized age. A P-value ≤0.05 was considered statistically significant.

3. Results

3.1. Population demographics

Cervical samples were collected from 945 women treated for infertility (IW) and 207 healthy oocyte donors (OD). The median ages of IW and OD were 33 years (range, 19–48 years) and 26 years (range, 18–35 years) respectively. The median age of oocyte recipients was 39 (range, 27–49 years). Of the 207 participants who were OD, 45 (21.7%) had donated oocytes.

3.2. HPV positivity rates

We detected the DNA of at least one of the 18 hrHPV genotypes or the 6 lrHPV genotypes in 20.3% of all samples (234/1152), 30.9% (64/207) of OD samples, and 18.0% (170/945) of IW samples. Of the 234 HPV positive samples, 210 (89.7%) were hrHPV positive, 38 (16.2%) were lrHPV positive, and 54 (23.1%) tested positive for hrHPV and lrHPV co-infection (Table 1).

Of the 54 HPV co-infected samples, 38 (70.4%) were infected with two HPV genotypes, 13 (24.1%) were infected with three HPV genotypes, and 3 (5.56%) were infected with four HPV genotypes. At least one hrHPV genotype was detected in all co-infection samples. HPV16 was the most frequent HPV genotype in both single-genotype infection and co-infections of OD and IW (Table 1).

The hrHPV prevalence was significantly higher in OD compared to IW (28.0% vs. 16.1%, P < 0.001). Similarly, the occurrence of hrHPV single-genotype infection was significantly higher in OD compared to IW (21.3% vs. 11.9%, P < 0.001) (Table 1). hrHPV positive women from both groups were significantly younger than hrHPV negative women (25 years vs. 27 years in OD; 31 years vs. 33 years in IW). hrHPV positive women had more sexual partners than hrHPV hrHPV negative women (4 vs. 3 in OD; 5 vs. 4 in IW). hrHPV positive oocyte donors had younger sexual partners (27 vs. 30, P = 0.007) and were more frequently childless (45.6% vs. 20.0%, P < 0.001) than hrHPV negative OD (Table 2).

Only 60 out of all 1110 women tested (5.4%) were vaccinated against HPV (Cervarix or Silgard/Gardasil). The difference between vaccination coverage in OD and IW was not significant (4.1% vs. 5.69%, P = 0.475).

3.3. HPV and IVF outcome

The pregnancy rate was lower in women treated with IVF (106/362, 29.3%) than in recipients of donated oocytes (35/87, 40.2%);
Table 1
Prevalence of hrHPV and lrHPV genotypes detected in cervical smear of oocyte donors and women treated for infertility.

| HPV genotype | Oocyte donors (n = 207) | Women treated for infertility (n = 945) |
|--------------|-------------------------|----------------------------------------|
| Single-genotype infection, n (%) | Co-infection, n (%) | Total, n (%) | Single-genotype infection, n (%) | Co-infection, n (%) | Total, n (%) | P-value (single-genotype infection) | P-value (co-infection) | P-value (total) |
| HPV16 | 8 (3.86) | 23 (2.43) | 31 (1.38) | 36 (3.81) | 0.360 | 0.111 | 0.089 |
| HPV18 | 1 (0.483) | 2 (0.212) | 1 (0.306) | 3 (0.317) | 0.448 | 0.327 | 0.221 |
| HPV31 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.221 |
| HPV33 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.221 |
| HPV35 | 5 (2.41) | 8 (0.847) | 13 (1.38) | 16 (1.69) | 0.067 | 0.427 | 0.059 |
| HPV45 | 1 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.221 |
| HPV51 | 4 (1.93) | 1 (0.483) | 5 (2.42) | 6 (0.847) | 0.067 | 0.427 | 0.059 |
| HPV52 | 1 (0.483) | 0 (0.212) | 1 (0.306) | 1 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV56 | 2 (0.966) | 0 (0.212) | 2 (0.306) | 2 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV59 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV66 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV68 | 4 (1.93) | 0 (0.212) | 4 (0.306) | 4 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV70 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV73 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV82 | 2 (0.966) | 0 (0.212) | 2 (0.306) | 2 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV83 | 2 (0.966) | 0 (0.212) | 2 (0.306) | 2 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV11 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV40 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV42 | 3 (1.45) | 0 (0.212) | 3 (0.306) | 3 (0.317) | 0.327 | 0.043 | 0.045 |
| HPV43 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| HPV44/55 | 0 (0.483) | 0 (0.212) | 0 (0.306) | 0 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| hrHPV | 6 (2.90) | 0 (0.212) | 6 (0.306) | 6 (0.317) | 0.327 | 0.043 | 0.045 |
| hrHPV | 44 (21.3) | 0 (0.212) | 44 (0.306) | 44 (0.317) | 0 (0.448) | 0.327 | 0.043 |
| hrHPV | 50 (24.2) | 0 (0.212) | 50 (0.306) | 50 (0.317) | 0 (0.448) | 0.327 | 0.043 |

Statistically significant data (P-value < 0.05) are highlighted in bold. High-risk HPV (hrHPV) includes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82 genotypes. HPV genotypes detectable by all test methods are highlighted in bold.

Low-risk HPV (lrHPV) includes HPV6, 11, 40, 42, 43, and 44/55 genotypes.

The HPV result for a given sample was obtained when at least two detection methods were concordant. The presence of hrHPV genotypes HPV53, 70, 73, 82 and lrHPV genotypes (HPV6, 11, 40, 42, 43, 44/55) were evaluated using only PapiloCheck® HPV-Screening.

NA- not available.

P = 0.065). The abortion rate was lower in spontaneously pregnant women (1/46, 2.17%), and women treated with IVF (2/106, 22.6%) than in recipients of donated oocytes (15/35, 42.9%, P < 0.001).

Nine of 46 women (19.6%) that had experienced spontaneous pregnancy were hrHPV positive. Similarly, ninety-seven of 535 women (18.1%) that had not received IVF treatment were hrHPV positive. Forty-six hrHPV positive women were found in the group of 362 women who received IVF treatment (12.7%; P = 0.065).

No association between hrHPV infection of OD and lower pregnancy rate or higher abortion rate was identified in recipients of donated oocytes (Table 3). Furthermore, no associations were identified between pregnancy or abortion rates and hrHPV infection or cause of infertility in IW subjected to IVF (Table 4). Similarly, no associations were identified between abortion rate and hrHPV positivity or cause of infertility in spontaneously pregnant women (Table 5). Finally, no association of hrHPV positivity with fertility outcome was confirmed by multivariate analysis (Tables 4 and 5).

4. Comments

This study investigates the prevalence of cervical HPV infection in oocyte donors, and women treated for infertility, focusing on the influence of hrHPV infection on fertility outcomes. Only a few studies evaluate HPV prevalence in women undergoing assisted reproduction [15–20], but no published study systematically investigates HPV prevalence in women treated for infertility in general. It is important to emphasize that two independent HPV detection methods were used for reliable HPV evaluation in all samples. Moreover, a third HPV detection method was used to confirm discordant results.

In our study, hrHPV infection was detected in 16.1% (152/945) of women treated for infertility, an incidence similar to the high hrHPV prevalence in cytologically negative findings reported in Czech women (15.6%, 203/1302) [21]. Nevertheless, hrHPV prevalence in oocyte donors was significantly higher than in women from infertile couples in this study and in the Czech women in the Tachezy study [21] (28.0%, 58/207, P < 0.001 [OD vs. IW]; P < 0.001 [OD vs. cytologically negative findings in Czech women]). The difference in hrHPV prevalence is unaffected by vaccination coverage (4.1% vs. 5.6%, P = 0.475) and could be caused by younger age of OD as compared to IW (26 years vs. 33 years, P < 0.001).

Higher HPV prevalence in women treated for infertility was observed in several studies. Perino et al. [18] reported that 17.5% (35/199) of women undergoing IVF tested HPV positive, with no distinction between hrHPV and lrHPV. Similarly to our findings, Spandorfer et al. [2006] [16] reported that 16.0% (71/106) of women undergoing IVF tested HPV positive. From this group, 14.1% were hrHPV positive and 7.6% were lrHPV positive.

In our study, women who became pregnant spontaneously (19.6%) and women not treated with IVF (18.1%) were more frequently hrHPV positive than women treated with IVF (12.7%, P = 0.077). Previous studies reported lower hrHPV prevalence in women undergoing IVF than in the cervical screening population (7.8% [23/294], and 7.0% [15/214] vs. 8.4% [192/2262] and 9.1% [18/197]) [15,17].
Table 2
Evaluation of questionnaires in the context of hrHPV positive status.

| Factor                              | Level       | hrHPV donors positive/ negative samples (median) | %     | P-value  | hrHPV donors positive/ negative samples (median) | %     | P-value  |
|-------------------------------------|-------------|-------------------------------------------------|-------|----------|-------------------------------------------------|-------|----------|
| Sexually transmitted disease in past| No          | 52/190                                          | 27.4  | 0.152*   | 123/792                                         | 15.5  | 0.374**  |
|                                     | Yes         | 5/10                                           | 50.0  |          | 22/114                                         | 19.3  |          |
| HPV vaccination                     | No          | 54/187                                          | 28.9  | 1.00*    | 138/862                                         | 16.0  | 0.958**  |
|                                     | Yes         | 2/8                                            | 25.0  |          | 9/52                                          | 17.3  |          |
| Surgery                             | No          | 22/93                                          | 23.7  | 0.630*   | 101/609                                         | 16.6  | 0.600**  |
|                                     | Yes         | 2/6                                            | 33.3  |          | 44/294                                         | 15.0  |          |
| Fertility alterations in family of treated woman | No | 14/63                                         | 22.2  | 1.00*    | 130/814                                         | 16.0  | 1.00**   |
|                                     | Yes         | 0/2                                            | 0     |          | 13/81                                         | 16.1  |          |
| Assisted reproduction in past       | No          | 11/50                                          | 22.0  | 1.00*    | 128/708                                         | 18.1  | 0.003**  |
|                                     | Yes         | 0/1                                            | 0     |          | 17/194                                         | 8.8   |          |
| Children                            | No          | 31/68                                          | 45.6  | <0.001** | 106/659                                         | 16.1  | 0.847**  |
|                                     | Yes         | 27/135                                          | 20.0  |          | 39/255                                         | 15.3  |          |
| Fertilization                       | Spontaneous | 27/130                                          | 20.8  | 1.00*    | 34/209                                         | 16.23 | 0.077*   |
|                                     | Assisted reproduction | 0/1                                      | 0     |          | 2/35                                         | 5.7   |          |
|                                     | Spontaneous and assisted reproduction | 0/2 | 0 | 2/5 | 40.0  |          |
| Abortion                            | No          | 42/140                                          | 30.0  | 0.474**  | 109/669                                         | 16.3  | 0.595**  |
|                                     | Yes         | 8/36                                           | 22.2  |          | 34/234                                         | 14.5  |          |
| Abortion stage                      | No          | 42/140                                          | 30.0  | 1.00*    | 109/669                                         | 16.3  | 0.544*   |
|                                     | Yes         | 4/14                                           | 28.6  |          | 10/54                                         | 18.2  |          |
|                                     | 6–N ≤ 12.week | 2/9                                   | 22.2  |          | 10/92                                         | 10.9  |          |
|                                     | >12.week     | 0/1                                            | 0     |          | 3/13                                         | 23.08 |          |
| Number of abortions                 | No          | 42/140                                          | 30.0  | 0.334*   | 109/669                                         | 16.3  | 0.911**  |
|                                     | 1           | 5/28                                           | 17.9  |          | 23/154                                         | 14.9  |          |
|                                     | ≥2          | 3/8                                            | 37.5  |          | 11/71                                         | 15.5  |          |

The P-value was calculated using Fisher’s exact test (*), Pearson’s test chi-squared test (**) or Wilcoxon exact test (***) as appropriate. Statistically significant data (P-value < 0.05) are highlighted in bold.

Vaccine-targeted HPV16 and HPV18 are the most frequent HPV genotypes worldwide (20.4–24.0% and 7.4–9.8%, respectively) [22–24] as well as in the Czech Republic (24.2–55.0% and 4.4–10.3%, respectively) [21,25,26]. In our study, HPV16 occurred most frequently (21.4% of HPV positive samples), and it was the most prevalent HPV genotype in infertile women treated with IVF in our study (27.1%, 13/48) and in Perino et al., 2011 report. HPV18 was most prevalent in Lundqvist et al., 2002 study [17] (40%, 6/15), and HPV16 was the second most prevalent (33.3%, 5/15). In this report, HPV18 was detected in only 2.14% of the samples.

In our study, which comprises to our knowledge the largest cohort of IV, no associations between hrHPV infection and lower pregnancy rate or higher abortion rate were found in hrHPV positive women treated with IVF or in oocyte recipients from hrHPV positive oocyte donors. Similarly to our study, several other studies found no associations between positive HPV detection and lower pregnancy rate [17–20]. On the other hand, Spandorfer et al., [16] reported significant associations between HPV infection and reduced pregnancy rate in women treated by IVF (23.5% [4/17] in HPV + vs. 57% [51/89] in HPV−, P = 0.02).

In our study, no associations among hrHPV infection and higher miscarriage risk were found. Our finding is in accordance with several other studies with large cohort of patients [16,17,19,27–29]. Perino et al., 2011 [18] found, however, higher abortion rate in HPV positive IVF-treated women as compared to HPV negative IVF-treated women (40.0% [6/15] vs. 13.7% [7/51], P = 0.0601). Higher abortion rate in HPV positive women was also reported by Comar et al., [20] (50.0% [1/2] vs. 18.2% [2/11])

Table 3
Fertility outcomes of oocyte recipients according to hrHPV status of oocyte donors.

| HPV status | No. of pregnancies (total = 35) | P-value | No. of abortions (total = 15) | P-value |
|------------|---------------------------------|---------|------------------------------|---------|
| Oocyte donors (n = 45) | hrHPV + OD (n = 10) | 8/17 (47.1%) | 0.716 | 4/8 (50.0%) | 0.954 |
| Oocyte recipients (n = 87) | Recipient (n = 17) | 27/70 (38.6%) | | | |

The P-value was calculated using Pearson’s chi-square test. OD = oocyte donor.
Table 4
Fertility outcomes in infertile women who become pregnant spontaneously according to cause of infertility, age and hrHPV status.

| Cause of infertility (total = 945) | HPV status | No. of spontaneous pregnancies (total = 46) | P-value* | Abortion (total = 1) | P-value* |
|----------------------------------|------------|----------------------------------------------|----------|----------------------|----------|
| Unexplained                      | hrHPV*     | 39/254 (15.4%)                              | 5/39 (12.8%) | 0.780                | 0/5 (5%)  |
| | hrHPV+     | 215/254 (84.6%)                            | 23/215 (10.7%) | 1/23 (4.35%)        | NA       |
| Female                           | hrHPV*     | 37/234 (15.8%)                              | 1/37 (2.7%)  | 0.697                | 0/1 (0%)  |
| | hrHPV+     | 197/234 (84.2%)                            | 11/197 (5.58%) | 0/1 (0%)            | NA       |
| Male                             | hrHPV*     | 38/258 (14.7%)                              | 2/38 (5.26%)  | 0.158                | 0/2 (0%)  |
| | hrHPV+     | 220/258 (85.3%)                            | 3/220 (1.36%)  | 0/1 (0%)            | NA       |
| Couple                           | hrHPV*     | 38/199 (19.1%)                              | 1/38 (2.63%)  | 0.191                | 0/1 (0%)  |
| | hrHPV+     | 161/199 (80.9%)                            | 0/161 (0%)     | 0/0 (0%)            | NA       |
| All                              | hrHPV*     | 152/945 (16.08%)                           | 9/152 (5.92%)  | 0.651                | 0/9 (0%)  |
| | hrHPV+     | 793/945 (8.39%)                            | 37/793 (4.67%)  | 1/37 (2.70%)        | 0.843    |

The P-value was calculated using Fisher’s exact test (*). NA – not available.

Table 5
Fertility outcomes of in vitro fertilization with embryo transfer in infertile women according to cause of infertility, age and hrHPV status.

| Cause of infertility (total = 362) | HPV status | No. of pregnancies (total = 106) | P-value* | Adjusted OR (95% CI) ** | P-value* | No. of abortions (total = 24) | P-value* | Adjusted OR (95% CI) ** | P-value* |
|----------------------------------|------------|----------------------------------|----------|-------------------------|----------|-------------------------------|----------|-------------------------|----------|
| Unexplained                      | hrHPV*     | 5/68 (7.35%)                    | 11/110 (10.3%) | 1.11 (0.71,1.75) | 0.648    | 1/2 (50%)                     | 0.395    | 1.65 (0.91,2.98)       | 0.114   |
| | hrHPV+     | 21/63 (33.3%)                 | 4/11 (36.4%)                     | 0.733    | 1.06 (0.79,1.42) | 0.688    | 1/4 (25%)                     | 1        | 0.93 (0.56,1.54)       | 0.775   |
| Female                           | hrHPV*     | 4/11 (36.4%)                    | 27/90 (30%)                     | 0.186    | 1.22 (0.95,1.58) | 0.126    | 1/6 (16.7%)                  | 1        | 0.89 (0.39,1.34)       | 0.582   |
| | hrHPV+     | 7/89 (81.3%)                   | 23/89 (25.8%)                    | 0.355    | 1.09 (0.86,1.40) | 0.473    | 0 (0%)                        | 0.539    | 0.80 (0.56,1.51)       | 0.241   |
| Male                             | hrHPV*     | 6/13 (46.15%)                   | 6/17 (35.3%)                     | 0.355    | 1.09 (0.86,1.40) | 0.473    | 0 (0%)                        | 0.539    | 0.80 (0.56,1.51)       | 0.241   |
| | hrHPV+     | 74/91 (81.3%)                  | 17/74 (23.0%)                    | 16/46 (39.1%)                    | 0.162    | 1.00 (0.96,1.27) | 0.182    | 3/18 (16.7%)                 | 0.722    | 0.95 (0.76,1.18)       | 0.616   |
| Couple                           | hrHPV*     | 18/46 (39.1%)                   | 3/12 (25%)                       | 1        | –                      | –        | 0/3 (0%)                      | 0.545    | –                      | –       |
| | hrHPV+     | 142/154 (92.2%)                | 36/142 (25.4%)                   | 11/36 (30.6%)                    | –        | –                      | –        | –                          | –       | –                      | –       |
| All                              | hrHPV*     | 88/316 (27.8%)                  | 21/88 (23.9%)                    | –        | –                      | –        | –                          | –       | –                      | –       |
| | hrHPV+     | 34/142 (25.4%)                 | 11/36 (30.6%)                    | –        | –                      | –        | –                          | –       | –                      | –       |

The P-value was calculated using Fisher’s exact test (*) or multivariate logistic regression model with categorized age as adjusting factor (**).

P = 0.423). Even though the number of patients in both studies is limited, the results of these studies align with studies reporting higher HPV prevalence in placentas of spontaneous abortions as compared to placentas from voluntarily terminated pregnancies [30] or in term deliveries [31].

Despite the lack of any association between HPV infection in women and pregnancy or abortion rates observed in this and other studies, circumstantial evidence suggests that HPV could affect fertility outcome [18,32]. It is possible that male HPV infection could influence the couple’s fertility outcome. Thus, future studies should consider analyzing male HPV infection in infertile couples and sperm donors.

In conclusion, and for the first time to our knowledge, we found significantly higher HPV prevalence in oocyte donors than in women treated for infertility and in the general Czech female population. No associations between HPV positive status of oocyte donors and pregnancy or abortion rates in recipients of oocytes from these donors were found. Likewise, no associations between HPV positive status and pregnancy or abortion rates were observed in IVF-treated women.
Acknowledgements

The authors thank the staff of Fertimed Ltd., Olomouc and Arleta IVF Ltd., Koštelec nad Orlicí especially Dagmar Ruzickova. We also thank the technicians and research staff of the Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc. Moreover, we thank all women who participated in the study.

This study was supported by following grants: Internal Grant Agency of Palacky University (LF_2019_003), Ministry of School, Education and Youth (LM2015064), Technological Agency of the Czech Republic (TE02000058), charity Cancer Research Czech Republic and the European Regional Development Fund-Project Enoch (No. CZ.02.1.01/0.0/0.0/16_019/0000868).

References

[1] Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 2007;22:1506–12.
[2] Mascarenhas MN, Chenou H, Mathers CD, Stevens GA. Measuring infertility in populations: constructing a standard definition for use with demographic and reproductive health surveys. Popul Health Metr 2012;10(17).
[3] Pellati D, Mylonakis I, Bertoloni G, Fiore C, Andrisani A, Ambrosini G, et al. Genital tract infections and infertility. Eur J Obstet Gynecol Reprod Biol 2008;140:3–11.
[4] Dejeux N, Jegou B. Viruses in the mammalian male genital tract and their effects on the reproductive system. Microbiol Mol Biol Rev 2001;65:208–31.
[5] Kapranos N, Petrakou E, Anastasiadou C, Kotronias D. Detection of herpes simplex virus, cytomegalovirus, and Epstein-Barr virus in the semen of men attending an infertility clinic. Fertil Steril 2003;79(Suppl 3):1566–70.
[6] Forman D, de MC Lacey CJ, Soermajtaram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(Suppl 5):F12–23.
[7] Rosales R, Rosales C. Immune therapy for human papillomavirus-related diseases. World J Clin Oncol 2014;5:1002–19.
[8] Schillman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907.
[9] Gizzo S, Ferrari B, Noventa M, Ferrari E, Patrelli TS, Garamemi M, et al. Male and couple fertility impairment due to HPV-DNA sperm infection: update on molecular mechanism and clinical impact—systematic review. Biomed Res Int 2014;2014:230263.
[10] Souho T, Benlemilh M, Bennani B. Human papillomavirus infection and fertility alteration: a systematic review. PLoS One 2015;10:e0126936.
[11] Gmbh RD. Cobas® 4800 HPV test. Roche Molecular Systems Inc; 2012.
[12] Jaworek H, Koudelakova V, Drabek J, Vychkova J, Zborilova B, Oborna I, et al. A head-to-head analytical comparison of cobas 4800 HPV, PapilloCheck HPV screening, and LMNX genotyping kit HPV GP for detection of human papillomavirus DNA in cervical and cervicovaginal swabs. J Mol Diagn 2018;20:349–58.
[13] Gmbh. PapilloCheck® high-risk. Greiner bio-one. 2012.
[14] BV. LMNX kit HPV GP HR. Diassay. 2014.
[15] Streicher E, Sterzik K, Maltihaner D, Hoyer H, Nindl I, Schneider A. Influence of ovarian stimulation on the detection of human papillomavirus DNA in cervical scrapes obtained from patients undergoing assisted reproductive techniques. Fertil Steril 1999;71:815–20.
[16] Spandorfer SD, Bongiovanni AM, Fasoulotis S, Rosenwaks Z, Ledger WJ, Witkin SS. Prevalence of cervical human papillomavirus in women undergoing in vitro fertilization and association with outcome. Fertil Steril 2006;86:765–7.
[17] Lundqvist M, Westin C, Lundkvist O, Simonberg N, Strand A, Andersson S, et al. Cytologic screening and human papilloma virus test in women undergoing artificial fertilization. Acta Obstet Gynecol Scand 2002;81:949–53.
[18] Perino A, Giovanelli L, Schilacci R, Ruvelo G, Fiorentino FP, Alimondi P, et al. Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes. Fertil Steril 2011;95:1845–8.
[19] Yang R, Wang Y, Qiao J, Liu P, Geng L, Guo YL. Does human papillomavirus infection do harm to in-vitro fertilization outcomes and subsequent pregnancy outcomes? Chin Med J (Engl) 2013;126:683–7.
[20] Connar M, Monasta L, Zanotta N, Vecchi BI, Ricci G, Zauli G. Human papillomavirus infection is associated with decreased levels of GM-CSF in cervico-vaginal fluid of infected women. J Clin Virol 2013;58:479–81.
[21] Tachezy R, Smahelova J, Kasprikova J, Salakova M. Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PLoS One 2013;8:e79156.
[22] de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–9.
[23] Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de SS. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202:1789–99.
[24] Guan P, Howell-Jones R, Li N, Bruni L, de SS, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131:2349–59.
[25] Tachovsky B, Hansikova E, Hajek T, Milyuskova I, Snahel M, Van RM, et al. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 1999;58:378–86.
[26] Ondryaska H, Koudelakova V, Drabek J, Vaneck P, Slavkovsky R, Hajduck M. [Utilization of self-testing kits for HPV testing in cervical cancer screening - pilot study]. Ceska Gynekol 2015;80:436–43.
[27] Conde-Feraraz L, Chan May AA, Carrillo-Martinez JR, Ayora-Talavera G, Gonzalez-Losa MR. Human papillomavirus infection and spontaneous abortion: a case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol 2013;170:468–73.
[28] Skoczynski M, Gozdziaka-Jozefak A, Kwasniakiewska A. Prevalence of human papillomavirus in spontaneously aborted products of conception. Acta Obstet Gynecol Scand 2011;90:1402–5.
[29] Ticconi C, Pietropolli A, Fabbri G, Capogna MV, Perno CF, Piccione E. Recurrent miscarriage and cervical human papillomavirus infection. Am J Reprod Immunol 2013;70:343–6.
[30] Hermonat PL, Han L, Wendel PJ, Quirk JC, Stern S, Lowery CL, et al. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes 1997;14:13–7.
[31] Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod 2008;23:709–15.
[32] Ambuhl LM, Baandrup U, Dybkjaer K, Blaakaer J, Uldbjerg N, Sorensen S. Human papillomavirus infection as a possible cause of spontaneous abortion and spontaneous preterm delivery. Infect Dis Obstet Gynecol 2016;2016:3086036.